Insilico Medicine is a clinical-stage biotech company using generative AI to accelerate drug discovery and development. Its Pharma.AI platform spans biology, chemistry, and clinical development, with AI-designed candidates advanced into trials.
UpMarket does not offer Insilico Medicine shares. This page covers Insilico Medicine's history before it went public.
Insilico Medicine became a public company on December 30, 2025 and trades on the Hong Kong Stock Exchange as 3696. UpMarket does not offer Insilico Medicine shares. This page covers Insilico Medicine's valuation and funding history before it went public.
Insilico Medicine listed on the Hong Kong Stock Exchange under the ticker 3696 on December 30, 2025.
See how Insilico Medicine's private-market valuation changed across funding rounds before it went public.
See reported funding rounds and revenue figures on this page, with their sources.
Accredited investors can review UpMarket's current pre-IPO offerings in companies that have not yet gone public.
Pre-IPO investments are illiquid, speculative, and involve risk of total loss of capital.
| Date | Round | PPS (split-adj.) | Valuation |
|---|---|---|---|
| Mar 2025 | Series E |
Insilico Medicine secured $110 million in an oversubscribed Series E round, with participation from a large equity fund of Value Partners Group and other new and existing backers. The funding followed earlier rounds including a $255 million Series C in 2021 and a $60 million Series D in 2022, underscoring continued capital access.
Insilico describes itself as a clinical-stage end-to-end AI-driven drug discovery company connecting biology, chemistry, and clinical trials analysis with next-generation AI systems. The company also cites three AI-powered platforms, PandaOmics, Chemistry42, and inClinico, as core product assets.
Insilico operates in drug discovery using AI, deep learning, and big data to develop therapies for cancer, fibrosis, immunity, central nervous system diseases, and age-related conditions. Deep Pharma Intelligence notes its focus on discovering traditional drugs through an end-to-end AI-backed platform, a large market spanning multiple high-need therapeutic areas.
Looking for companies that are still private? Browse UpMarket's pre-IPO company directory. Accredited investors only.
Browse the directory →UpMarket curates and conducts independent diligence on every investment opportunity before it reaches the platform.
We review every offering's strategy, risk management, liquidity, fees, valuation methodology, tax matters, and all third-party providers: legal counsel, auditor, administrator, and custodian.
We offer investments exclusively from disciplined managers that pursue unique strategies across an array of asset classes.
Our goal is to empower you to build a portfolio that best meets your individual investment objectives.
Yes. Insilico Medicine became a public company on December 30, 2025 and trades on the Hong Kong Stock Exchange under the ticker 3696. UpMarket does not offer Insilico Medicine shares.
Insilico Medicine's share price is set on the public market under the ticker 3696. The prices shown on this page are historical private-market prices from before it went public.
No. Insilico Medicine is now a public company and UpMarket does not offer its shares. Accredited investors interested in companies that have not yet gone public can review UpMarket's current pre-IPO offerings.
Insilico Medicine is now publicly traded, so its shares can be bought and sold on the Hong Kong Stock Exchange and their price can change significantly. Review Insilico Medicine's public filings and consult a financial advisor before investing. UpMarket does not offer Insilico Medicine shares.
In a pre-IPO transaction, accredited investors purchase shares from existing shareholders (such as employees, early investors, or other holders) through secondary market platforms. The company itself does not issue new shares in these transactions. UpMarket facilitates these trades as a FINRA-registered broker-dealer, handling compliance, documentation, and settlement on behalf of both parties.
Insilico Medicine became a public company on December 30, 2025, so shares held before the listing can generally be sold on the public market once any lock-up period ends. The exact terms depend on how the shares are held, for example directly or through a fund.
UpMarket does not offer Insilico Medicine shares. The minimum for most pre-IPO offerings on UpMarket is $50,000.
Insilico Medicine's valuation is now set by its public share price on the Hong Kong Stock Exchange. The figures on this page show its valuation history before it went public.
Insilico Medicine is a clinical-stage biotech using generative AI to accelerate drug discovery and development, with $85.8M in 2024 revenue and a $110M Series E to scale Pharma.AI. Insilico Medicine is now a public company, and UpMarket does not offer its shares.